Catalent has announced plans to acquire Cook Pharmica for $950m.

The acquisition will strengthen Catalent’s position in the biologics development and analytical services sectors.

Both the acquirer and target entities are pharmaceutical companies based in the US.

"Biopharmaceutical company Ultragenyx Pharmaceutical plans to acquire rare disease company Dimension Therapeutics for $138m."

Biopharmaceutical company Ultragenyx Pharmaceutical plans to acquire rare disease company Dimension Therapeutics for $138m.

The acquisition will strengthen the company’s business and help in accelerating the development of its therapeutics.

Both companies involved in the acquisition are based in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.